☆ 4.4 Review

Synthalin: a lost lesson for glucagon suppression in diabetes therapeutics

JOURNAL OF PHARMACY AND PHARMACOLOGY (2023)

When insulin isn't enough: targeting glucagon in type 1 diabetes

Michelle Van Name et al.

Summary: A phase 2 study failed to achieve its primary endpoint, but the treatment demonstrated clinically relevant improvements in glycemic control, suggesting its potential use as an adjunct to insulin therapy.

NATURE MEDICINE (2022)

添加到收藏夹

Article Biochemistry & Molecular Biology

Alpha-cells and therapy of diabetes: Inhibition, antagonism or death?

Natalie Klempel et al.

Summary: Absolute or relative hyperglucagonaemia is a characteristic of both Type 1 and Type 2 diabetes. Therapeutics that target glucagon secretion or biological action may be effective in treating diabetes. However, these medications may have off-target adverse effects. Compounds that enhance the transdifferentiation of glucagon secreting alpha-cells towards an insulin positive beta-cell phenotype could also help control excess glucagon secretion in diabetes.

PEPTIDES (2022)

添加到收藏夹

Review Medicine, General & Internal